# Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

> **NCT06574503** · PHASE3 · RECRUITING · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 748 (estimated)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** GP681 40mg
- **DRUG:** GP681 Simulant

## Key facts

- **NCT ID:** NCT06574503
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 748 (ESTIMATED)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574503, "Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06574503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*